



(22) Date de dépôt/Filing Date: 2001/03/09

(41) Mise à la disp. pub./Open to Public Insp.: 2001/09/13

(45) Date de délivrance/Issue Date: 2005/10/18

(30) Priorité/Priority: 2000/03/13 (60/188,892) US

(51) Cl.Int.⁷/Int.Cl.⁷ C07D 233/32, A61K 31/495, A61K 31/4709, A61K 31/4439, A61K 31/427, A61P 29/00, A61K 31/422, A61K 31/4184, A61K 31/4166, A61P 19/02, A61P 35/00, C07D 235/02, C07D 405/02, C07D 403/02, C07D 417/02, C07D 413/02, C07D 409/02, C07D 401/12, C07D 491/107, C07D 495/10, C07D 487/10, C07D 401/06, C07D 473/00


(72) Inventeurs/Inventors:
LAIRD, ELLEN RUTH, US;
ROBINSON, RALPH PELTON, JR., US

(73) Propriétaire/Owner:
PFIZER PRODUCTS INC., US

(74) Agent: SMART & BIGGAR

(54) Titre : COMPOSES HYDROXAMIDES D'ACIDE 2-OXO-IMIDAZOLIDINE-4-CARBOXYLIQUE INHIBITEURS DE LA METALLOPROTEINASE MATRICIELLE

(54) Title: 2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID HYDROXAMIDE COMPOUNDS THAT INHIBIT MATRIX METALLOPROTEINASES




(57) Abrégé/Abstract:

Disclosed are novel compounds of the formula: (see formula I) (wherein R¹ is aryl, heteroaryl, arylalkyl, heteroarylalkyl, arylaryl or the like; R² and R³ are each H or alkyl or together form a spiro ring; R⁴ is H or alkyl), and pharmaceutically acceptable salts and solvates thereof, that are useful, for example, as matrix metalloproteinase inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treatment for diseases such as osteoarthritis, rheumatoid arthritis, cancer, osteoporosis, tissue ulceration, restinosis, periodontal disease, inflammation, epidermolysis bullosa, scleritis, stroke, Alzheimer's disease, and the like, characterized by inappropriate matrix metalloproteinase activity. Processes for the synthesis of compounds of formula (I) are also disclosed.

64680-1237

ABSTRACT

Disclosed are novel compounds of the formula:



5

(wherein R^1 is aryl, heteroaryl, arylalkyl, heteroarylalkyl, arylaryl or the like; R^2 and R^3 are each H or alkyl or together form a spiro ring; R^4 is H or alkyl), and pharmaceutically acceptable salts and solvates thereof, that are useful, for example, as matrix metalloproteinase inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treatment for diseases such as osteoarthritis, rheumatoid arthritis, cancer, osteoporosis, tissue ulceration, restinosis, periodontal disease, inflammation, epidermolysis bullosa, scleritis, stroke, Alzheimer's disease, and the like, characterized by inappropriate matrix metalloproteinase activity. Processes for the synthesis of compounds of formula (I) are also disclosed.

10

15

5 2-OXO-IMIDAZOLIDINE-4-CARBOXYLIC ACID HYDROXAMIDE COMPOUNDS THAT
 INHIBIT MATRIX METALLOPROTEINASES

Background of the Invention

 The present invention relates to 2-oxo-imidazolidine-4-carboxylic acid hydroxamide
10 derivatives, and to pharmaceutical compositions comprising such derivatives, and to the use
 of such derivatives in the treatment of arthritis, inflammation, cancer, and other diseases as
 described below.

 The compounds of the present invention are inhibitors of zinc metalloendopeptidases,
 especially those belonging to the matrix metalloproteinase (also called MMP or matrixin) and
15 reprolysin (also known as adamylsin) subfamilies of the metzincins (Rawlings, et al., Methods
 in Enzymology, 248, 183-228 (1995) and Stocker, et al., Protein Science, 4, 823-840 (1995)).

 The MMP subfamily of enzymes, currently contains seventeen members (MMP-1,
 MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13, MMP-14,
 MMP-15, MMP-16, MMP-17, MMP-18, MMP-19, MMP-20). The MMP's are most well known
20 for their role in regulating the turn-over of extracellular matrix proteins and as such play
 important roles in normal physiological processes such as reproduction, development and
 differentiation. In addition, the MMP's are expressed in many pathological situations in which
 abnormal connective tissue turnover is occurring. For example, MMP-13, an enzyme with
 potent activity at degrading type II collagen (the principal collagen in cartilage), has been
25 demonstrated to be overexpressed in osteoarthritic cartilage (Mitchell, et al., J. Clin. Invest.,
 97, 761 (1996)). Other MMPs (MMP-2, MMP-3, MMP-8, MMP-9, MMP-12) are also
 overexpressed in osteoarthritic cartilage and inhibition of some or all of these MMP's is
 expected to slow or block the accelerated loss of cartilage typical of joint diseases such as
 osteoarthritis or rheumatoid arthritis.

30 Overexpression of certain metalloproteinases is also associated with metastasis of
 tumor cells. It is believed that such activity is essential to the invasion of healthy tissues.
 Inhibition of the activity of some or all of these proteinases is expected to limit the spread of
 malignant cells. Additionally, certain metalloproteinases are necessary for angiogenesis, the
 process whereby, for example, a growing tumor obtains additional blood supply through new
35 vascularization. Therefore inhibition of these enzymes is expected to slow or arrest tumor
 growth.

 The compounds of the invention are also expected to usefully inhibit additional
 classes of enzymes having important roles in both normal and pathological processes. For
 example, the mammalian reprolysins are known as ADAMs (A Disintegrin And
40 Metalloproteinase) (Wolfberg, et al., J. Cell Biol., 131, 275-278 (1995)) and contain a

5 disintegrin domain in addition to a metalloproteinase-like domain. To date, twenty three distinct ADAM's have been identified. ADAM-17, also known as tumor necrosis factor-alpha converting enzyme (TACE), is the most well known ADAM.

ADAM-17 (TACE) is responsible for cleavage of cell bound tumor necrosis factor-alpha (TNF- α , also known as cachectin). TNF- α is recognized to be involved in many
10 infectious and auto-immune diseases (W. Friers, FEBS Letters, 285, 199 (1991)). Furthermore, it has been shown that TNF- α is the prime mediator of the inflammatory response seen in sepsis and septic shock (Spooner, et al., Clinical Immunology and Immunopathology, 62 S11 (1992)). There are two forms of TNF- α , a type II membrane protein of relative molecular mass 26,000 (26 kD) and a soluble 17 kD form generated from
15 the cell bound protein by specific proteolytic cleavage. The soluble 17 kD form of TNF- α is released by the cell and is associated with the deleterious effects of TNF- α . This form of TNF- α is also capable of acting at sites distant from the site of synthesis. Thus, inhibitors of TACE prevent the formation of soluble TNF- α and prevent the deleterious effects of the soluble factor.

20 In a further example, aggrecanase, is an enzyme that is important in the degradation of cartilage aggrecan. Aggrecanase is believed to be an ADAM. The loss of aggrecan from the cartilage matrix is an important factor in the progression of joint diseases such as osteoarthritis and rheumatoid arthritis and inhibition of aggrecanase is expected to slow or block the loss of cartilage in tissues affected by these diseases.

25 Other ADAMs that have shown expression in pathological situations include ADAM TS-1 (Kuno, et al., J. Biol. Chem., 272, 556-562 (1997)), and ADAM's 10, 12 and 15 (Wu, et al., Biochem. Biophys. Res. Comm., 235, 437-442, (1997)). As knowledge of the expression, physiological substrates and disease association of the ADAM's increases the full significance of the role of inhibition of this class of enzymes will be appreciated.

30 The compounds of the invention are useful in the treatment of arthritis (including osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions, inflammation, allergic contact hypersensitivity, cancer (such as solid tumor cancer including
35 colon cancer, breast cancer, lung cancer and prostate cancer and hematopoietic malignancies including leukemias and lymphomas), tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic aneurysm and brain aortic aneurysm), congestive heart failure, myocardial

-3-

5 infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neuro-degenerative disorders (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns,
10 diabetes, tumor invasion, tumor growth, tumor metastasis, corneal scarring, scleritis, AIDS, sepsis or septic shock.

The compounds of the present invention are also useful in the treatment of diseases in which inhibition of MMP's and/or ADAM's will provide therapeutic benefit, such as those characterized by matrix metalloproteinase or ADAM expression.

15 Matrix metalloproteinase and reprotin inhibitors are well known in the literature. Specifically, European Patent Publication 606,046, published July 13, 1994 refers to ceratin heterocyclic MMP inhibitors. PCT Publication WO 98/08825 and WO 98/08815, both published March 5, 1998, refer to certain cyclic hydroxamic acid MMP inhibitors. United States Patent 5,861,510, issued January 19, 1999, refers to cyclic arylsulfonylamino
20 hydroxamic acids that are useful as MMP inhibitors. PCT Publication WO 98/34918, published August 13, 1998, refers to cyclic hydroxamic acids including certain dialkyl substituted compounds that are useful as MMP inhibitors.

PCT publications WO 96/27583 and WO 98/07697, published March 7, 1996 and February 26, 1998, respectively, refer to arylsulfonyl hydroxamic acids. PCT publication WO
25 98/03516, published January 29, 1998, refers to phosphinates with MMP activity. PCT publication 98/33768, published August 6, 1998, refers to N-unsubstituted arylsulfonylamino hydroxamic acids. European Patent Publication EP 935,963, published August 18, 1999 refers to the use of MMP-13 selective inhibitors for the treatment of osteoarthritis. United States Patent Nos. 6,229,025, 6,118,016 and 6,228,246, refer to methods of preparing hydroxamic acids. European Patent Publication EP 1081137 refers to MMP, Aggreacanase and TACE inhibitors and to additional methods of preparing hydroxamic acids. PCT Publication WO 00/09492 refers to heterocyclic hydroxamic acids.

It is recognized that different combinations of MMP's and ADAM's are expressed in different pathological situations. As such, inhibitors with specific selectivities for individual ADAM's and/or MMP's may be preferred for individual diseases. For example, rheumatoid
40 arthritis is an inflammatory joint disease characterized by excessive TNF levels and the loss


-4-

5 of joint matrix constituents. In this case, a compound that inhibits TACE and aggrecanase as well as MMP's such as MMP-13 may be the preferred therapy. In contrast, in a less inflammatory joint disease such as osteoarthritis, compounds that inhibit matrix degrading MMP's such as MMP-13 but not TACE may be preferred.

Summary of the Invention

10

The present invention relates to a compound according to formula (I)



or a pharmaceutically acceptable salt or solvate thereof, wherein

R¹ is selected from the groups consisting of


- 15 (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₁-C₉)heteroaryl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₉)heteroaryl, (C₁-C₉)heteroaryl(C₁-C₉)heteroaryl, (C₆-C₁₀)aryloxy(C₆-C₁₀)aryl, (C₁-C₉)heteroaryloxy(C₆-C₁₀)aryl, (C₆-C₁₀)aryloxy(C₁-C₉)heteroaryl, (C₁-C₉)heteroaryloxy(C₁-C₉)heteroaryl, (C₆-C₁₀)aryloxy(C₁-C₆)alkyl, (C₁-C₉)heteroaryloxy(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl(C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(C₁-C₆)alkyl(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₆)alkyl(C₁-C₉)heteroaryl, (C₁-C₉)heteroaryl(C₁-C₆)alkyl(C₁-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₁-C₉)heteroaryl, (C₁-C₉)heteroaryl(C₁-C₆)alkoxy(C₁-C₉)heteroaryl, (C₆-C₁₀)aryloxy(C₁-C₆)alkyl(C₆-C₁₀)aryl, (C₁-C₉)heteroaryloxy(C₁-C₆)alkyl(C₆-C₁₀)aryl, (C₆-C₁₀)aryloxy(C₁-C₆)alkyl(C₁-C₉)heteroaryl, (C₁-C₉)heteroaryloxy(C₁-C₆)alkyl(C₁-C₉)heteroaryl, (C₆-C₁₀)aryl(C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₁-C₉)heteroaryl(C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₉)heteroaryl(C₁-C₆)alkyl, (C₁-C₉)heteroaryl(C₁-C₉)heteroaryl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₁-C₆)alkyl, and (C₁-C₉)heteroaryl(C₁-C₆)alkoxy(C₁-C₆)alkyl,
- 20
- 25

wherein, independently, each of the ring carbon atoms of said (C₆-C₁₀)aryl and (C₁-C₉)heteroaryl moieties that is capable of forming an additional bond is optionally substituted by a group selected from fluoro, chloro, bromo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, perfluoro(C₁-C₃)alkyl, and perfluoro(C₁-C₃)alkoxy;

30

R² and R³ are each independently selected from hydrogen and (C₁-C₆)alkyl, or taken together form a spiro ring of the formula

-5-



5

wherein X is a bond, CH₂, O, S, NH or N(C₁-C₆)alkyl, n is independently 1 or 2, and m is independently 1 or 2; and

R⁴ is hydrogen or (C₁-C₆)alkyl.

10

In a preferred aspect of the invention, R¹ is selected from the group consisting of (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₆-C₁₀)aryloxy(C₆-C₁₀)aryl, (C₁-C₉)heteroaryloxy(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl, and (C₁-C₉)heteroaryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl.

In further preferred aspects of the invention, R¹ is selected:

15


(a) from the group consisting of 4-[(C₆-C₁₀)aryl]phenyl, 4-[(C₆-C₁₀)aryloxy]phenyl and 4-[(C₆-C₁₀)aryl(C₁-C₆)alkoxy]phenyl; or

(b) from the group consisting of 4-[(C₁-C₉)heteroaryl]phenyl, 4-[(C₁-C₉)heteroaryloxy]phenyl and 4-[(C₁-C₉)heteroaryl(C₁-C₆)alkoxy]phenyl.

Highly preferred examples include those wherein R¹ is 4-(4-fluorophenoxy)phenyl, 4-(4-chlorophenoxy)phenyl and 4-(naphthalen-2-yloxy)phenyl.

20

In a preferred aspect of the invention R² and R³ taken together form a spiro ring of the formula



wherein X is a bond, CH₂, O, S, NH or N(C₁-C₆)alkyl, n is 1 or 2, and m is 1 or 2, such that n is the same as m.


25

In a further preferred aspect of the invention, R² and R³ are selected from hydrogen and (C₁-C₆)alkyl. According to this aspect of the invention, it is preferred that R² be the same as R³, that is, R² and R³ are each hydrogen, or are each (C₁-C₆)alkyl, such that R² is the same as R³.

30

In preferred examples of the invention R⁴ is (C₁-C₆)alkyl; R⁴ is hydrogen; and R², R³ and R⁴ are each hydrogen.

- 5 In a highly preferred embodiment of the invention, the ring carbon to which R⁴ attaches possesses the *R* configuration. Accordingly, preferred compounds of the invention are provided according to the formula (I')



- 10 wherein the preference in selection of groups R¹, R², R³ and R⁴ is as aforementioned with respect to compounds wherein stereospecific configuration is unspecified at the ring carbon atom to which R⁴ attaches.

Accordingly, preferred compounds of the invention include

- | | | |
|----|---|------|
| | (4 <i>R</i>)-1-[4-(4-Fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide; | acid |
| 15 | (4 <i>R</i>)-1-[4-(Naphthalen-1-yloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide; | acid |
| | (4 <i>R</i>)-1-[4-(Naphthalen-2-yloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide; | acid |
| | (4 <i>R</i>)-1-(4-Methoxybenzyl)-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide; | |
| 20 | (4 <i>R</i>)-1-[3-(4-Fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide; | acid |
| | (4 <i>R</i>)-1-Naphthalen-2-ylmethyl-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide; | |
| | (4 <i>R</i>)-1-(4'-Fluorobiphenyl-4-ylmethyl)-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide; | acid |
| 25 | (4 <i>R</i>)-1-(4-Benzoyloxybenzyl)-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide; and | |
| | (4 <i>R</i>)-1-[4-(2-Chloro-4-fluorobenzyloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide; | acid |
| | Additional preferred compounds of the invention include: | |
| 30 | (4 <i>R</i>)-1-[4-(4-Chlorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide; | acid |
| | (4 <i>R</i>)-1-[4-(4-Fluorophenoxy)benzyl]-2-oxo-7-oxa-1,3-diazaspiro[4.4]nonane-4-carboxylic acid hydroxyamide; | |
| | (4 <i>R</i>)-2-Oxo-1-[4-(pyridin-4-yloxy)benzyl]imidazolidine-4-carboxylic acid hydroxyamide; | acid |

- 5 (4*R*)-4-Methyl-2-oxo-1-[4-(pyridin-4-yloxy)benzyl]imidazolidine-4-carboxylic acid
hydroxyamide;
- (4*R*)-5,5-Dimethyl-2-oxo-1-[4-(pyridin-4-yloxy)benzyl]imidazolidine-4-carboxylic acid
hydroxyamide;
- 10 (4*R*)-1-[4-(4-Fluorophenoxy)benzyl]-5,5-dimethyl-2-oxo-imidazolidine-4-carboxylic
acid hydroxyamide;
- (4*R*)-1-[4-(4-Chlorophenoxy)benzyl]-5,5-dimethyl-2-oxo-imidazolidine-4-carboxylic
acid hydroxyamide;
- (4*R*)-1-[4-(4-Fluorophenoxy)benzyl]-4-methyl-2-oxo-imidazolidine-4-carboxylic acid
hydroxyamide;
- 15 (4*R*)-1-[4-(4-Chlorophenoxy)benzyl]-4-methyl-2-oxo-imidazolidine-4-carboxylic acid
hydroxyamide;
- (4*R*)-1-[4-(4-Fluorophenoxy)benzyl]-2-oxo-1,3-diazaspiro[4.4]nonane-4-carboxylic
acid hydroxyamide;
- (4*R*)-1-[4-(4-Chlorophenoxy)benzyl]-2-oxo-1,3-diazaspiro[4.4]nonane-4-carboxylic
acid hydroxyamide;
- 20 (4*R*)-1-[4-(4-Fluorophenoxy)benzyl]-4,5,5-trimethyl-2-oxo-imidazolidine-4-carboxylic
acid hydroxyamide;
- (4*R*)-1-[4-(4-Chlorophenoxy)benzyl]-4,5,5-trimethyl-2-oxo-imidazolidine-4-carboxylic
acid hydroxyamide;
- 25 (4*R*)-4-Methyl-1-[4-(naphthalen-2-yloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid
hydroxyamide;
- (4*R*)-5,5-Dimethyl-1-[4-(naphthalen-2-yloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic
acid hydroxyamide;
- (4*R*)-1-[4-(5-Fluoropyridin-2-yloxy)benzyl]-4-methyl-2-oxo-imidazolidine-4-carboxylic
acid hydroxyamide;
- 30 (4*R*)-2-Oxo-1-(4-pyridin-4-ylbenzyl)imidazolidine-4-carboxylic acid hydroxyamide and
(4*R*)-2-Oxo-1-(4-pyridylmethyl)imidazolidine-4-carboxylic acid hydroxyamide.

The term "alkyl", as used herein, unless otherwise indicated, includes saturated
monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations
35 thereof.

The term "alkoxy", as used herein, includes O-alkyl groups wherein "alkyl" is as defined
above.

The term "aryl" as used herein, unless otherwise indicated, includes an organic radical
derived from a monocyclic or bicyclic (C₆-C₁₀) aromatic hydrocarbon by removal of one hydrogen,
40 such as phenyl or naphthyl, optionally substituted by substituents selected from the group

5 consisting of fluoro, chloro, bromo, perfluoro(C₁-C₆)alkyl (including trifluoromethyl), (C₁-C₆)alkoxy, perfluoro(C₁-C₃)alkoxy (including trifluoromethoxy and difluoromethoxy) and (C₁-C₆)alkyl. Unless otherwise indicated, selection of each optional substituent is independent of selection of any other optional substituents, and preferably the number of substituents is zero, or is between 1 and 3.

10 The term "heteroaryl" as used herein, unless otherwise indicated, includes an organic radical derived from a monocyclic or bicyclic (C₁-C₉) aromatic heterocyclic compound by removal of one hydrogen, such as pyridyl, furyl, pyrrolyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, 15 benzthiazolyl and benzoxazolyl, optionally substituted by substituents selected from the group consisting of fluoro, chloro, trifluoromethyl, (C₁-C₆)alkoxy, trifluoromethoxy, difluoromethoxy and (C₁-C₆)alkyl. Unless otherwise indicated, selection of each optional substituent is independent of selection of any other optional substituents, and preferably the number of substituents is zero, or is between 1 and 2.

20 "A suitable substituent" is intended to mean a chemically and pharmaceutically acceptable functional group i.e., a moiety that does not substantially negate the inhibitory activity of the inventive compounds, and/or a moiety that contributes properties useful to production, storage, or use of the inventive compounds as pharmaceuticals. Such suitable substituents may be determined by those skilled in the art. Illustrative examples of suitable substituents include, 25 but are not limited to, alkyl groups, hydroxy groups, alkylthio groups, alkoxy groups, groups, carboxy groups, amino groups, alkyl- and dialkylamino groups, carbamoyl groups, alkylcarbonyl groups, alkoxycarbonyl groups, alkylaminocarbonyl groups, dialkylamino carbonyl groups, arylcarbonyl groups, aryloxy carbonyl groups, alkylsulfonyl groups, an arylsulfonyl groups and the like.

30 The compound of formula I may have chiral centers and therefore exist in different enantiomeric forms. This invention relates to all optical isomers, tautomers and stereoisomers of the compounds of formula I and mixtures thereof.

The present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I. The acids which are used to prepare the pharmaceutically 35 acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate,

- 5 benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)]salts.

The invention also relates to base addition salts of formula I. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with
10 such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.

15 The subject invention also includes isotopically-labelled compounds, which are identical to those recited in Formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen,
20 phosphorous, fluorine and chlorine, such as ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , and ^{36}Cl , respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labelled compounds of the present invention, for example those
25 into which radioactive isotopes such as ^3H and ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., ^2H , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced
30 dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds of Formula I of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.

35 The present invention also relates to a pharmaceutical composition for the treatment of a condition selected from the group consisting of arthritis (including osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions, allergic contact hypersensitivity, cancer (such as
40 solid tumor cancer including colon cancer breast cancer, lung cancer and prostate cancer

5 and hematopoietic malignancies including leukemias and lymphomas), tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic aneurysm and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neuro-degenerative
10 disorders (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, diabetes, tumor invasion, tumor growth, tumor metastasis, corneal scarring, scleritis, AIDS, sepsis and
15 septic shock in a mammal, including a human, comprising an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in such treatments and a pharmaceutically acceptable carrier.

The present invention also relates to a pharmaceutical composition for the treatment of diseases characterized by metalloproteinase activity (preferably MMP-13) and other diseases
20 characterized by mammalian reprotolysin activity (preferably Aggrecanase activity most preferably Aggrecanase activity) in a mammal, including a human, comprising an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in such treatments and a pharmaceutically acceptable carrier.

The present invention also relates to a pharmaceutical composition for the inhibition of
25 (a) matrix metalloproteinases or other metalloproteinases involved in matrix degradation, or (b) a mammalian reprotolysin (such as aggrecanase or ADAM's TS-1, 10, 12, 15 and 17, most preferably Aggrecanase) in a mammal, including a human, comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

30 The present invention also relates to a method for treating a condition selected from the group consisting of arthritis (including osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions, allergic contact hypersensitivity, inflammation, cancer (such as solid tumor cancer
35 including colon cancer breast cancer, lung cancer and prostate cancer and hematopoietic malignancies including leukemias and lymphomas), tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic aneurysm and brain aortic aneurysm), congestive heart failure, myocardial infarction,
40 stroke, cerebral ischemia, head trauma, spinal cord injury, neuro-degenerative disorders (acute

5 and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, diabetes, tumor invasion, tumor growth, tumor metastasis, corneal scarring, scleritis, AIDS, sepsis and septic shock in a
10 mammal, including a human, comprising administering to said mammal an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in treating such a condition.

The present invention also relates to the treatment of diseases characterized by matrix metalloproteinase activity (preferably MMP-13 activity) and other diseases characterized by
15 mammalian reprolysin activity (preferably Aggrecanase activity) in a mammal, including a human, comprising administering to said mammal an amount of a compound of formula I or a pharmaceutically acceptable salt thereof effective in treating such a condition.

The present invention also relates to a method for the inhibition of (a) matrix metalloproteinases or other metalloproteinases involved in matrix degradation, or (b) a
20 mammalian reprolysin (such as aggrecanase or ADAM's TS-1, 10, 12, 15 and 17, preferably Aggrecanase) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

The present invention also relates to a method of inhibiting the cleavage of TNF- α from cell membranes in a mammal comprising administering to such mammal an effective amount
25 of compound of formula I that inhibits Aggrecanase.

The present invention also relates to a method of treating arthritis in a mammal, comprising administering to such mammal an effective amount of an Aggrecanase inhibitor, wherein said Aggrecanase inhibitor selectively inhibits Aggrecanase in preference to MMP-1.

The present invention also relates to a method of treating arthritis in a mammal, comprising administering to such mammal an effective amount of an Aggrecanase inhibitor,
30 wherein said Aggrecanase inhibitor selectively inhibits Aggrecanase at least ten times as well as MMP-1.

The present invention also relates to a method of treating arthritis in a mammal, comprising administering to such mammal an effective amount of an Aggrecanase inhibitor,
35 wherein said Aggrecanase inhibitor selectively inhibits Aggrecanase and MMP-13 in preference to MMP-1.

The present invention also relates to a method of treating arthritis in a mammal, comprising administering to such mammal an effective amount of an Aggrecanase inhibitor, wherein said Aggrecanase inhibitor selectively inhibits Aggrecanase and MMP-13 at least ten
40 times as well as MMP-1.

5 The present invention also relates to a method of treating arthritis in a mammal, comprising administering to such mammal an effective amount of a hydroxamic acid Aggrecanase inhibitor, wherein said Aggrecanase inhibitor selectively inhibits Aggrecanase and MMP-13 in preference to MMP-1.

10 The present invention also relates to a method of treating arthritis in a mammal, comprising administering to such mammal an effective amount of a hydroxamic acid Aggrecanase inhibitor, wherein said Aggrecanase inhibitor selectively inhibits Aggrecanase and MMP-13 at least ten times as well as MMP-1.

15 The term "treating", as used herein, refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, refers to the act of treating, as "treating" is defined immediately above.

20 This invention also encompasses pharmaceutical compositions containing prodrugs of compounds of the formula I. This invention also encompasses methods of treating or preventing disorders that can be treated or prevented by the inhibition of matrix metalloproteinases or the inhibition of mammalian reprotolysin comprising administering prodrugs of compounds of the formula I. Compounds of formula I having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of compounds of formula I. The amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of formula I through the carbonyl carbon prodrug sidechain.

35 One of ordinary skill in the art will appreciate that the compounds of the invention are useful in treating a diverse array of diseases. One of ordinary skill in the art will also appreciate that when using the compounds of the invention in the treatment of a specific disease that the compounds of the invention may be combined with various existing therapeutic agents used for that disease.

40 For the treatment of rheumatoid arthritis, the compounds of the invention may be combined with agents such as TACE inhibitors, TNF- α inhibitors such as anti-TNF monoclonal antibodies and TNF receptor immunoglobulin molecules (such as Enbrel®), COX-2 inhibitors low dose methotrexate, lefunimide, hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold.

The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of osteoarthritis. Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents
5 (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as Aspirin*, COX-2 inhibitors such as
10 celecoxib and rofecoxib, analgesics and intraarticular therapies such as corticosteroids and hyaluronic acids such as Hyalgan* and Synvisc*.

The compounds of the present invention may also be used in combination with anticancer agents such as endostatin
15 and angiostatin or cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, Taxol*, Taxotere* and alkaloids, such as vincristine, and antimetabolites such as methotrexate.

The compounds of the present invention may also be
20 used in combination with cardiovascular agents such as calcium channel blockers, lipid lowering agents such as statins, fibrates, beta-blockers, Ace inhibitors, Angiotensin-2 receptor antagonists and platelet aggregation inhibitors.

The compounds of the present invention may also be
25 used in combination with CNS agents such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as deprenyl, L-dopa, Requip*, miratex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar*, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists,
30 Nicotine agonists, Dopamine agonists and inhibitors of neuronal

*Trade-mark

50190-65

13a

nitric oxide synthase), and anti-Alzheimer's drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metryfonate.

5 The compounds of the present invention may also be used in combination with osteoporosis agents such as roloxifene, droloxifene or fosomax and immunosuppressant agents such as FK-506 and rapamycin.


10 The pharmaceutical compositions of the present invention may be contained in a commercial package, optionally together with instructions for the therapeutic use thereof for treating a condition, as herein described.

Detailed Description of the Invention

15 The following reaction schemes illustrates the preparation of the compounds of the present invention. Unless otherwise indicated, R^1 , R^2 , and R^3 and R^4 in the reaction schemes and the discussion that follows are defined as above.

-14-

Scheme 1



5 General Reaction Conditions

Referring to Scheme 1, compounds of the formula I may be prepared from compounds of the formula II by removal of the hydroxyamide protecting group P^2 where P^2 can be tert-butyl, benzyl, 2-trimethylsilylethyl or allyl. The preferred protecting group is 2-trimethylsilylethyl. When P^2 is benzyl, removal of the hydroxyamide protecting group is
10 carried out by hydrogenolysis using catalytic palladium on barium sulfate in a polar solvent such as methanol at a temperature of about 20°C. When P^2 is 2-trimethylsilylethyl, removal of the hydroxyamide protecting group is carried out using boron trifluoride etherate in an inert solvent such as methylene chloride or chloroform, preferably methylene chloride, at a temperature from about 0°C to about 50°C, preferably about 20°C. When P^3 is tert-butyl,
15 removal of the protecting group is performed using a strong acid such as trifluoroacetic acid in an inert solvent such as methylene chloride or chloroform, preferably methylene chloride, at a temperature from about 0°C to about 50°C, preferably about 20°C. When P^2 is allyl, removal of the protecting group may be carried out by treatment with tributyltin hydride and acetic acid in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride.

20 Referring to Scheme 1, compounds of the formula II may be prepared from carboxylic acids of the formula III by reaction with a hydroxylamine derivative of the formula P^2ONH_2 in the presence of an activating agent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 1-hydroxybenztriazole in an aprotic solvent, such as methylene chloride or N,N-dimethylformamide, preferably methylene chloride. The reaction is conducted at a temperature
25 of about 0°C to about 50°C, preferably about 20°C. The hydroxylamine of the formula P^2ONH_2 is preferably generated *in situ* from a salt form, such as the hydrochloride, in the presence of a base, such as triethylamine or diisopropylethylamine, preferably diisopropylethylamine.

The compounds of the formula III may be prepared from compounds of the formula IV by removal of the carboxylic acid protecting group P^1 where P^1 is methyl, ethyl or tert-butyl,
30 preferably tert-butyl. When P^1 is methyl or ethyl, removal of the the protecting group P^1 is carried out by reaction with excess of a metal hydroxide, such as sodium hydroxide or lithium hydroxide, preferably lithium hydroxide, in a protic solvent, such as aqueous ethanol, at a temperature of about 0° C to about 100° C, preferably about 20° C. In cases where the solubility of IV is limited, tetrahydrofuran may be added to the reaction mixture as a co-solvent. When P^1 is tert-butyl,
35 removal of the protecting group P^1 is carried out by treatment with a strong acid such as hydrochloric acid or trifluoroacetic acid, preferably trifluoroacetic acid, in an inert solvent such as chloroform or methylene chloride, preferably methylene chloride. The reaction is carried out at a temperature of about 0° C to about 50° C, preferably about 20° C.

The compounds of the formula IV may be prepared from compounds of the formula V
40 by hydrogenation under an atmosphere of hydrogen in the presence of a catalyst in a reaction

5 inert solvent. Suitable catalysts include palladium on carbon, palladium hydroxide on carbon or palladium black, preferably palladium on carbon. Suitable solvents include an alcohol such as ethanol, or methanol, preferably methanol. The aforesaid reaction may be performed at a pressure from about 1 to about 5 atmospheres, preferably about 3 atmospheres. Suitable temperatures for the aforesaid reaction range from about 20°C (room temperature) to about
10 60°C, preferably about 20°C.

The compounds of formula V may be prepared from the compounds of formula VI by reaction with a base and an alkylating agent of the formula $R^1(CH_2)_nX$, wherein X is a leaving group such as Br, I or para-toluenesulfonate. Suitable bases include potassium carbonate, cesium carbonate, potassium hexamethyldisilazide, or sodium hydride, preferably potassium
15 carbonate. The reaction is stirred in a polar solvent, such as acetone, N,N-dimethylformamide, or N-methylpyrrolidin-2-one at a temperature from about 0°C to about 50°C, preferably about 20°C.


The compounds of formula V wherein R^4 is (C_1-C_6) alkyl can be obtained via alkylation of compounds of the formula V wherein R^4 is hydrogen. The alkylation is carried out by
20 reaction of an intermediate of formula V wherein R^4 is hydrogen with an alkyl halide of the formula $CH_3(CH_2)_nX$ wherein n is 0 to 5 and X is bromo or iodo. The aforesaid reaction is run in the presence of a hindered strong base such as lithium diisopropylamide or lithium hexamethyldisilazide in an inert solvent such as diethyl ether or tetrahydrofuran at a temperature from about -78°C to about 0°C, preferably about -78°C.

25 The compounds of the formula VI can be prepared from compounds of the formula VII by reaction with benzyl chloroformate in the presence of a base such as triethylamine or diisopropylethylamine, preferably triethylamine and a catalytic amount of 4-dimethylaminopyridine. The aforesaid reaction is carried out in a solvent such as tetrahydrofuran, methylene chloride or chloroform, preferably methylene chloride, at a
30 temperature from about 0°C to about 20°C, preferably about 20°C.

The compounds of the formula VII may be obtained from diamino compounds of the formula VIII by reaction with phosgene, carbonyl diimidazole or triphosgene, preferably triphosgene in the presence of a base such as pyridine or triethylamine, preferably triethylamine. The aforesaid reaction is carried out in a solvent such as tetrahydrofuran,
35 methylene chloride or chloroform, preferably tetrahydrofuran, at a temperature from about 0°C to about 20°C, preferably about 20°C.


Compounds of formula VIII where P^1 is methyl or ethyl, R^4 is hydrogen, and R^2 and R^3 are independently (C_1-C_6) alkyl can be obtained from ketones of the formula R^2R^3CO wherein R^2 and R^3 are independently (C_1-C_6) alkyl. Similarly, compounds of formula VIII where P^1 is
40 methyl or ethyl, R^4 is hydrogen, and R^2 and R^3 taken together form a spiro ring of the formula

-17-



5

wherein X is a bond, CH₂, O, S, NH or N(C₁-C₆)alkyl, n is independently 1 or 2, and m is independently 1 or 2, can be prepared from cyclic ketones of the formula (IX) wherein X is a bond, CH₂, O, S, NH or N(C₁-C₆)alkyl, n is independently 1 or 2, and m is independently 1 or 2.




10

The procedures are the same as those described by Schollkopf et al in the case where R² and R³ are methyl (*Liebigs Ann. Chem.* 1973, 611 and *Liebigs Ann. Chem.* 1977, 1183).

Compounds of formula VIII wherein P¹ is methyl or ethyl, and R³ and R⁴ are hydrogen may be prepared from compounds of the formula X:

15



wherein R³ is (C₁-C₆)alkyl. The procedures are the same as those described by Mohan et al in the case where R³ is isopropyl (*J. Med. Chem.* 1991, 34, 2402). Several methods for preparing compounds of formula IX are known in the literature, for example Shin et al, *Bull. Chem. Soc. Jpn.* 1972, 45, 3595.

20

The compound of formula VI wherein P¹ is tert-butyl and R², R³ and R⁴ are hydrogen is known in the literature as the S enantiomer (Shiba et al. *Bull. Chem. Soc. Japan*, 1968, 41, 2748). The corresponding R enantiomer is prepared as described for the S enantiomer, using N-benzyloxycarbonyl-D-asparagine in place of N-benzyloxycarbonyl-L-asparagine as starting material.

25

The compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base

30

5 compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful
10 evaporation of the solvent, the desired solid salt is obtained.

The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate,
15 lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.

Those compounds of the formula I which are also acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts
20 include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic compounds of formula I. These non-toxic base salts include those derived from such
25 pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic
30 compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields.

For administration to mammals, including humans, for the inhibition of matrix
35 metalloproteinases, for inhibition of production of tumor necrosis factor (TNF) and, for example, for the inhibition of mammalian reprotolysin (preferably inhibition of aggrecanase), a variety of a variety of conventional routes may be used including oral, parenteral (e.g., intravenous, intramuscular or subcutaneous), buccal, anal and topical. In general, the compounds of the invention (hereinafter also known as the active compounds) will be administered at dosages
40 between about 0.1 and 25 mg/kg body weight of the subject to be treated per day, preferably

5 from about 0.3 to 5 mg/kg. Preferably the active compound will be administered orally or parenterally. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

The compounds of the present invention can be administered in a wide variety of
10 different dosage forms, in general, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed
15 along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules;
20 preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and
25 various like combinations thereof. In the case of animals, they are advantageously contained in an animal feed or drinking water in a concentration of 5-5000 ppm, preferably 25 to 500 ppm.

For parenteral administration (intramuscular, intraperitoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared. Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in
30 aqueous propylene glycol may be employed. The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by
35 standard pharmaceutical techniques well known to those skilled in the art. In the case of animals, compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1 to 50 mg/kg/day, advantageously 0.2 to 10 mg/kg/day given in a single dose or up to 3 divided doses.

5 The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

 For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump
10 spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or
15 nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

 The ability of the compounds of formula I or their pharmaceutically acceptable salts
20 (hereinafter also referred to as the compounds of the present invention) to inhibit metalloproteinases or mammalian reprotolysin and, consequently, demonstrate their effectiveness for treating diseases characterized by metalloproteinase or the production of tumor necrosis factor is shown by the following in vitro assay tests.

25

BIOLOGICAL ASSAYS

Inhibition of soluble TNF Production

 The ability of the compounds or the pharmaceutically acceptable salts thereof to inhibit the cellular production/release of TNF and, consequently, demonstrate their effectiveness for treating diseases involving the dysregulated of TNF is shown by the following in vitro assay:

30

Method for the evaluation of recombinant TNF α Converting Enzyme Activity.

1) Preparation of recombinant TACE:

 A DNA fragment coding for the signal sequence, prodomain and catalytic domain of TACE (amino acids 1-473), was amplified by polymerase chain reaction using a human lung cDNA library as a template. The amplified fragment was cloned into pFastBac vector. The
35 DNA sequence of the insert was confirmed for both the strands. A bacmid prepared using pFastBac in E. coli DH10Bac was transfected into SF9 insect cells. The virus particles were amplified to P1, P2, P3 stages. The P3 virus was infected into both Sf9 and High Five insect cells and grown at 27°C for 48 hours. The medium was collected and used for assays and further purification.

5 2) Preparation of fluorescent quenched substrate:

A model peptidic TNF- α substrate (LY-LeucineAlanineGlutamineAlanineValine-ArginineSerine-SerineLysine(CMTR)-Arginine (LY=Lucifer Yellow; CMTR= 5-carboxytetramethyl Rhodamine)) was prepared and the concentration estimated by absorbance at 560 nm (E_{560} , 60,000 M⁻¹CM⁻¹) according to the method of Geoghegan, KF, 10 "Improved method for converting an unmodified peptide to an energy-transfer substrate for a proteinase." Bioconjugate Chem. 7, 385-391 (1995). This peptide encompasses the cleavage site on pro-TNF which is cleaved in vivo by TACE.

 3) Enzyme reaction.

The reaction, carried out in a 96 well plate (Dynatech), was comprised of 70 μ l of 15 buffer solution (25 mM Hepes-HCl, pH7.5, plus 20 μ M ZnCl₂), 10 μ l of 100 μ M fluorescent quenched substrate, 10 μ l of a DMSO (5%) solution of test compound, and an amount of r-TACE enzyme which will cause 50% cleavage in 60 minutes - in a total volume of 100 μ l. The specificity of the enzyme cleavage at the amide bond between alanine and valine was verified by HPLC and mass spectrometry. Initial rates of cleavage were monitored by measuring the 20 rate of increase in fluorescence at 530 nm (excitation at 409 nm) over 30 minutes. The experiment was controlled as follows: 1) for background fluorescence of substrate; 2) for fluorescence of fully cleaved substrate; 3) for fluorescence quenching or augmentation from solutions containing test compound.

Data was analyzed as follows. The rates from the non-test compound containing 25 "control" reactions were averaged to establish the 100% value. The rate of reaction in the presence of test compound was compared to that in the absence of compound, and tabulated as "percent of non-test compound containing control. The results were plotted as "% of control" vs. the log of compound concentration and a half-maximal point or IC₅₀ value determined. The IC₅₀ for the above assay is a measure of the inhibition of the TNF- α 30 proteolytic activity of TACE. Blockage of binding of TNF- α to TACE as used herein is as described in United States Patents 5,830,742, issued November 3, 1998.

Monocyte Assay

Human mononuclear cells were isolated from anti-coagulated human blood using a one-step Ficoll^{*}-hypaque separation technique. (2) The mononuclear cells were washed three times 35 in Hanks balanced salt solution (HBSS) with divalent cations and resuspended to a density of 2×10^6 /ml in HBSS containing 1% BSA. Differential counts determined using the Abbott Cell Dyn 3500 analyzer indicated that monocytes ranged from 17 to 24% of the total cells in these preparations.

*Trade-mark

5 180m of the cell suspension was aliquoted into flat bottom 96 well plates (Costar*). Additions of compounds and LPS (100 ng/ml final concentration) gave a final volume of 200 μ l. All conditions were performed in triplicate. After a four hour incubation at 37°C in an humidified CO₂ incubator, plates were removed and centrifuged (10 minutes at approximately 250 x g) and the supernatants removed and assayed for TNF- α using the R&D ELISA Kit.

10 MMP Assays

Collagenase-3 (matrix metalloproteinase-13) selective inhibitors as used herein refer to agents which exhibit at least a 100 fold selectivity for the inhibition of collagenase-3 enzyme activity over collagenase-1 enzyme activity and a potency of less than 100 nM as defined by the IC₅₀ results from the MMP-13/MMP-1 fluorescence assays described below. Collagenase-3
15 selective inhibitors can be identified by screening the inhibitors of the present invention through the MMP-13/MMP-1 fluorescence assays described below and selecting those agents with MMP-13/MMP-1 inhibition IC₅₀ ratios of 100 or greater and potency of less than 100 nM.

Non-selective collagenase inhibitors as used herein refer to agents which exhibit less than a 100 fold selectivity for the inhibition of collagenase-3 enzyme activity over collagenase-1
20 enzyme activity or a potency of more than 100nM as defined by the IC₅₀ results from the MMP-13/MMP-1 fluorescence assays described below.

The ability of collagenase inhibitors to inhibit collagenase activity is well known in the art. The following assays may be used to identify matrix metalloproteinase inhibitors.

Inhibition of Human Collagenase (MMP-1)

25 Human recombinant collagenase is activated with trypsin using the following ratio: 10 μ g trypsin per 100 μ g of collagenase. The trypsin and collagenase are incubated at room temperature for 10 minutes then a five fold excess (50 μ g/10 μ g trypsin) of soybean trypsin inhibitor is added.

10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted
30 using the following Scheme:

10 mM -----> 120 μ M -----> 12 μ M -----> 1.2 μ M -----> 0.12 μ M

Twenty-five microliters of each concentration is then added in triplicate to appropriate wells of a 96 well microfluor plate. The final concentration of inhibitor will be a 1:4 dilution after addition of enzyme and substrate. Positive controls (enzyme, no inhibitor) are set up in wells
35 D1-D6 and blanks (no enzyme, no inhibitors) are set in wells D7-D12.

Collagenase is diluted to 400 ng/ml and 25 μ l is then added to appropriate wells of the microfluor plate. Final concentration of collagenase in the assay is 100 ng/ml.

Substrate (DNP-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂) is made as a 5 mM stock in dimethyl sulfoxide and then diluted to 20 mM in assay buffer. The assay is initiated by
*Trade-mark

- 5 the addition of 50 μ l substrate per well of the microfluor plate to give a final concentration of 10 μ M.

Fluorescence readings (360 nm excitation, 460 nm emission) were taken at time 0 and then at 20 minute intervals. The assay is conducted at room temperature with a typical assay time of 3 hours.

- 10 Fluorescence vs time is then plotted for both the blank and collagenase containing samples (data from triplicate determinations is averaged). A time point that provides a good signal (the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine IC_{50} values. The zero time is used as a blank for each compound at each concentration and these values are subtracted from the 120 minute data. Data is plotted as
- 15 inhibitor concentration vs % control (inhibitor fluorescence divided by fluorescence of collagenase alone x 100). IC_{50} 's are determined from the concentration of inhibitor that gives a signal that is 50% of the control.

If IC_{50} 's are reported to be $<0.03 \mu$ M then the inhibitors are assayed at concentrations of 0.3 μ M, 0.03 μ M, 0.03 μ M and 0.003 μ M.

20 Inhibition of Gelatinase (MMP-2)

Inhibition of gelatinase activity is assayed using the Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂ substrate (10 μ M) under the same conditions as inhibition of human collagenase (MMP-1).

- 25 72kD gelatinase is activated with 1 mM APMA (p-aminophenyl mercuric acetate) for 15 hours at 4°C and is diluted to give a final concentration in the assay of 100 mg/ml. Inhibitors are diluted as for inhibition of human collagenase (MMP-1) to give final concentrations in the assay of 30 μ M, 3 μ M, 0.3 μ M and 0.03 μ M. Each concentration is done in triplicate.

Fluorescence readings (360 nm excitation, 460 emission) are taken at time zero and then at 20 minutes intervals for 4 hours.

- 30 IC_{50} 's are determined as per inhibition of human collagenase (MMP-1). If IC_{50} 's are reported to be less than 0.03 μ M, then the inhibitors are assayed at final concentrations of 0.3 μ M, 0.03 μ M, 0.003 μ M and 0.003 μ M.

Inhibition of Stromelysin Activity (MMP-3)

- 35 Inhibition of stromelysin activity is based on a modified spectrophotometric assay described by Weingarten and Feder (Weingarten, H. and Feder, J., Spectrophotometric Assay for Vertebrate Collagenase, Anal. Biochem. 147, 437-440 (1985)). Hydrolysis of the thiopeptolide substrate [Ac-Pro-Leu-Gly-SCH[CH₂CH(CH₃)₂]CO-Leu-Gly-OC₂H₅] yields a mercaptan fragment that can be monitored in the presence of Ellman's reagent.

5 Human recombinant prostromelysin is activated with trypsin using a ratio of 1 μ l of a 10 mg/ml trypsin stock per 26 mg of stromelysin. The trypsin and stromelysin are incubated at 37°C for 15 minutes followed by 10 μ l of 10 μ g/ml soybean trypsin inhibitor for 10 minutes at 37°C for 10 minutes at 37°C to quench trypsin activity.

Assays are conducted in a total volume of 250 μ l of assay buffer (200 mM sodium chloride, 50 mM MES, and 10 mM calcium chloride, pH 6.0) in 96-well microliter plates. Activated stromelysin is diluted in assay buffer to 25 μ g/ml. Ellman's reagent (3-Carboxy-4-nitrophenyl disulfide) is made as a 1M stock in dimethyl formamide and diluted to 5 mM in assay buffer with 50 μ l per well yielding at 1 mM final concentration.

10 mM stock solutions of inhibitors are made in dimethyl sulfoxide and diluted serially in assay buffer such that addition of 50 μ L to the appropriate wells yields final concentrations of 3 μ M, 0.3 μ M, 0.003 μ M, and 0.0003 μ M. All conditions are completed in triplicate.

A 300 mM dimethyl sulfoxide stock solution of the peptide substrate is diluted to 15 mM in assay buffer and the assay is initiated by addition of 50 μ l to each well to give a final concentration of 3 mM substrate. Blanks consist of the peptide substrate and Ellman's reagent without the enzyme. Product formation was monitored at 405 nm with a Molecular Devices UVmax plate reader.

IC₅₀ values were determined in the same manner as for collagenase.

Inhibition of MMP-13

Human recombinant MMP-13 is activated with 2 mM APMA (p-aminophenyl mercuric acetate) for 1.5 hours, at 37°C and is diluted to 400 mg/ml in assay buffer (50 mM Tris, pH 7.5, 200 mM sodium chloride, 5 mM calcium chloride, 20 μ M zinc chloride, 0.02% brij). Twenty-five microliters of diluted enzyme is added per well of a 96 well microfluor plate. The enzyme is then diluted in a 1:4 ratio in the assay by the addition of inhibitor and substrate to give a final concentration in the assay of 100 mg/ml.

30 10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted in assay buffer as per the inhibitor dilution scheme for inhibition of human collagenase (MMP-1): Twenty-five microliters of each concentration is added in triplicate to the microfluor plate. The final concentrations in the assay are 30 μ M, 3 μ M, 0.3 μ M, and 0.03 μ M.

35 Substrate (Dnp-Pro-Cha-Gly-Cys(Me)-His-Ala-Lys(NMA)-NH₂) is prepared as for inhibition of human collagenase (MMP-1) and 50 μ l is added to each well to give a final assay concentration of 10 μ M. Fluorescence readings (360 nm excitation; 450 emission) are taken at time 0 and every 5 minutes for 1 hour.

Positive controls consist of enzyme and substrate with no inhibitor and blanks consist of substrate only.

5 IC₅₀'s are determined as per inhibition of human collagenase (MMP-1). If IC₅₀'s are reported to be less than 0.03 μ M, inhibitors are then assayed at final concentrations of 0.3 μ M, 0.03 μ M, 0.003 μ M and 0.0003 μ M.

Collagen film MMP-13 Assay

10 Rat type I collagen is radiolabeled with ¹⁴C acetic anhydride (T.E. Cawston and A.J. Barrett, Anal. Biochem., 99, 340-345 (1979)) and used to prepare 96 well plates containing radiolabeled collagen films (Barbara Johnson-Wint, Anal. Biochem., 104, 175-181 (1980)). When a solution containing collagenase is added to the well, the enzyme cleaves the insoluble collagen which unwinds and is thus solubilized. Collagenase activity is directly proportional to the amount of collagen solubilized, determined by the proportion of
15 radioactivity released into the supernatant as measured in a standard scintillation counter. Collagenase inhibitors are, therefore, compounds which reduce the radioactive counts released with respect to the controls with no inhibitor present. One specific embodiment of this assay is described in detail below.

20 For determining the selectivity of compounds for MMP-13 versus MMP-1 using collagen as a substrate, the following procedure is used. Recombinant human proMMP-13 or proMMP-1 is activated according to the procedures outlined above. The activated MMP-13 or MMP-1 is diluted to 0.6 μ g/ml with buffer (50 mM Tris pH 7.5, 150 mM NaCl, 10 mM CaCl₂ , 1 μ M ZnCl₂, 0.05% Brij-35, 0.02% sodium azide).

25 Stock solutions of test compound (10mM) in dimethylsulfoxide are prepared. Dilutions of the test compounds in the Tris buffer, above, are made to 0.2, 2.0, 20, 200, 2000 and 20000 nM.

30 100 μ l of appropriate drug dilution and 100 μ l of diluted enzyme are pipetted into wells of a 96 well plate containing collagen films labeled with ¹⁴C-collagen. The final enzyme concentration is 0.3 μ g/ml while the final drug concentration is 0.1, 1.0, 10, 100, 1000 nM. Each drug concentration and control is analyzed in triplicate. Triplicate controls are also run for the conditions in which no enzyme is present and for enzyme in the absence of any compound.

35 The plates are incubated at 37°C for a time period such that around 30 - 50% of the available collagen is solubilized - determined by counting additional control wells at various time points. In most cases around 9 hours of incubation are required. When the assay has progressed sufficiently, the supernatant from each well is removed and counted in a scintillation counter. The background counts (determined by the counts in the wells with no enzyme) are subtracted from each sample and the % release calculated in relation to the wells with enzyme only and no inhibitor. The triplicate values for each point are averaged and

- 5 the data graphed as percent release versus drug concentration. IC_{50} 's are determined from the point at which 50% inhibition of release of radiolabeled collagen is obtained.

To determine the identity of the active collagenases in cartilage conditioned medium, assays were carried out using collagen as a substrate, cartilage conditioned medium containing collagenase activity and inhibitors of varying selectivity. The cartilage conditioned
10 medium was collected during the time at which collagen degradation was occurring and thus is representative of the collagenases responsible for the collagen breakdown. Assays were carried out as outlined above except that instead of using recombinant MMP-13 or recombinant MMP-1, cartilage conditioned medium was the enzyme source.

IL-1 Induced Cartilage Collagen Degradation From Bovine Nasal Cartilage

- 15 This assay uses bovine nasal cartilage explants which are commonly used to test the efficacy of various compounds to inhibit either IL-1 induced proteoglycan degradation or IL-1 induced collagen degradation. Bovine nasal cartilage is a tissue that is very similar to articular cartilage, i.e. chondrocytes surrounded by a matrix that is primarily type II collagen and aggrecan. The tissue is used because it: (1) is very similar to articular cartilage, (2) is readily
20 available, (3) is relatively homogeneous, and (4) degrades with predictable kinetics after IL-1 stimulation.

Two variations of this assay have been used to assay compounds. Both variations give similar data. The two variations are described below:

Variation 1

- 25 Three plugs of bovine nasal cartilage (approximately 2 mm diameter x 1.5 mm long) are placed into each well of a 24 well tissue culture plate. One ml of serumless medium is then added to each well. Compounds are prepared as 10 mM stock solutions in DMSO and then diluted appropriately in serumless medium to final concentrations, e.g., 50, 500 and 5000 nM. Each concentration is assayed in triplicate.
- 30 Human recombinant IL-1 α (5ng/mL) (IL-1) is added to triplicate control wells and to each well containing drug. Triplicate control wells are also set up in which neither drug nor IL-1 are added. The medium is removed and fresh medium containing IL-1 and the appropriate drug concentrations is added on days 6, 12, 18 and 24 or every 3 - 4 days if necessary. The media removed at each time point is stored at -20°C for later analysis. When the cartilage in
35 the IL-1 alone wells has almost completely resorbed (about day 21), the experiment is terminated. The medium, is removed and stored. Aliquots (100 μ l) from each well at each time point are pooled, digested with papain and then analyzed for hydroxyproline content. Background hydroxyproline (average of wells with no IL-1 and no drug) is subtracted from each data point and the average calculated for each triplicate. The data is then expressed as
40 a percent of the IL-1 alone average value and plotted. The IC_{50} is determined from this plot.

5 Variation 2

The experimental set-up is the same as outlined above in Variation 1, until day 12. On day 12, the conditioned medium from each well is removed and frozen. Then one ml of phosphate buffered saline (PBS) containing 0.5 µg/ml trypsin is added to each well and incubation continued for a further 48 hours at 37°C. After 48 hours incubation in trypsin, the
 10 PBS solution is removed. Aliquots (50 µl) of the PBS/trypsin solution and the previous two time points (days 6 and 12) are pooled, hydrolyzed and hydroxyproline content determined. Background hydroxyproline (average of wells with no IL-1 and no drug) is subtracted from each data point and the average calculated for each triplicate. The data is then expressed as a percent of the IL-1 alone average value and plotted. The IC₅₀ is determined from this plot.
 15 In this variation, the time course of the experiment is shortened considerably. The addition of trypsin for 48 hours after 12 days of IL-1 stimulation likely releases any type II collagen that has been damaged by collagenase activity but not yet released from the cartilage matrix. In the absence of IL-1 stimulation, trypsin treatment produces only low background levels of collagen degradation in the cartilage explants.

20 Inhibition of Human 92 kD Gelatinase (MMP-9)

Inhibition of 92 kD gelatinase (MMP-9) activity is assayed using the Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂ substrate (10 µM) under similar conditions as described above for the inhibition of human collagenase (MMP-1).

Human recombinant 92 kD gelatinase (MMP-9, gelatinase B) is activated for 2 hours
 25 with 1mM p-aminophenyl-mercuric acetate (from a freshly prepared 100 mM stock in 0.2 N NaOH) at 37 C.

10 mM dimethylsulfoxide stock solutions of inhibitors are diluted serially in assay buffer (50 mM TRIS, pH 7.5, 200 mM NaCl, 5 mM CaCl₂, 20 µM ZnCl₂, 0.02% BRIJ-35 (vol./vol.)) using the following scheme:

30 10 mM---→ 120 µM---→ 12 µM---→ 1.2 µM---→ 0.12 µM

Further dilutions are made as necessary following this same scheme. A minimum of four inhibitor concentrations for each compound are performed in each assay. 25 µL of each concentration is then added to triplicate wells of a black 96 well U-bottomed microfluor plate. As the final assay volume is 100 µL, final concentrations of inhibitor are the result of a further
 35 1:4 dilution (i.e. 30 µM ---→ 3 µM ---→ 0.3 µM ---→ 0.03 µM, etc.). A blank (no enzyme, no inhibitor) and a positive enzyme control (with enzyme, no inhibitor) are also prepared in triplicate.

-28-

- 5 Activated enzyme is diluted to 100 ng/mL in assay buffer, 25 μ L per well is added to appropriate wells of the microplate. Final enzyme concentration in the assay is 25 ng/mL (0.27 nM).

 A five mM dimethylsulfoxide stock solution of substrate (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂) is diluted in assay buffer to 20 μ M. The assay is initiated by addition of 50 μ L of
10 diluted substrate yielding a final assay concentration of 10 μ M substrate. A 0 time fluorescence reading (320 excitation; 390 emission) is immediately taken and subsequent readings are taken every fifteen minutes at room temperature with a PerSeptive Biosystems CytoFluor Multi-Well Plate Reader with the gain at 90 units.

- The average value of fluorescence of the enzyme and blank are plotted versus time.
15 An early time point on the linear part of this curve is chosen for IC₅₀ determinations. The 0 time point for each compound at each dilution is subtracted from the latter time point and the data then expressed as percent of enzyme control (inhibitor fluorescence divided by fluorescence of positive enzyme control x 100). Data is plotted as inhibitor concentration versus percent of enzyme control. IC₅₀'s are defined as the concentration of inhibitor that
20 gives a signal that is 50% of the positive enzyme control.

Aggrecanase Assay

- Primary porcine chondrocytes from articular joint cartilage are isolated by sequential trypsin and collagenase digestion followed by collagenase digestion overnight and are plated at 2 X 10⁵ cells per well into 48 well plates with 5 μ Ci / ml ³⁵S (1000 Ci/mmol) sulphur in type I
25 collagen coated plates. Cells are allowed to incorporate label into their proteoglycan matrix (approximately 1 week) at 37°C, under an atmosphere of 5% CO₂.

 The night before initiating the assay, chondrocyte monolayers are washed two times in DMEM/ 1% PSF/G and then allowed to incubate in fresh DMEM /1% FBS overnight.

- The following morning chondrocytes are washed once in DMEM/1%PSF/G. The final
30 wash is allowed to sit on the plates in the incubator while making dilutions.

 Media and dilutions can be made as described in the Table below.

Control Media	DMEM alone (control media)
IL-1 Media	DMEM + IL-1 (5 ng/ml)
Drug Dilutions	Make all compounds stocks at 10 mM in DMSO. Make a 100 μM stock of each compound in DMEM in 96 well plate. Store in freezer overnight. The next day perform serial dilutions in DMEM with IL-1 to 5 μM, 500 nM, and 50 nM. Aspirate final wash from wells and add 50 μl of compound from above dilutions to 450 μl of IL-1 media in appropriate wells of the 48 well plates. Final compound concentrations equal 500 nM, 50 nM, and 5 nM. All samples completed in triplicate with Control and IL-1 alone samples on each plate.

5

Plates are labeled and only the interior 24 wells of the plate are used. On one of the plates, several columns are designated as IL-1 (no drug) and Control (no IL-1, no drug). These control columns are periodically counted to monitor ^{35} S-proteoglycan release. Control and IL-1 media are added to wells (450 μ l) followed by compound (50 μ l) so as to initiate the assay. Plates are incubated at 37°C, with a 5% CO₂ atmosphere.

10

At 40-50 % release (when CPM from IL-1 media is 4-5 times control media) as assessed by liquid scintillation counting (LSC) of media samples, the assay is terminated (9-12 hours). Media is removed from all wells and placed in scintillation tubes. Scintillate is added and radioactive counts are acquired (LSC). To solubilize cell layers, 500 μ l of papain digestion buffer (0.2 M Tris, pH 7.0, 5 mM EDTA, 5 mM DTT, and 1 mg/ml papain) is added to each well. Plates with digestion solution are incubated at 60°C overnight. The cell layer is removed from the plates the next day and placed in scintillation tubes. Scintillate is then added, and samples counted (LSC).

15

The percent of released counts from the total present in each well is determined. Averages of the triplicates are made with control background subtracted from each well. The percent of compound inhibition is based on IL-1 samples as 0% inhibition (100% of total counts).

20

The compounds of the present invention that were tested had IC₅₀ of less than 1 μ M, preferably less than 50nM in at least one of the assays described above. The compounds of the present invention also possess differential activity (i.e. are selective for) for one or more reprotolysin or MMP. Selectivity as used herein refers to the ratio of the IC₅₀ inhibitory results from two or more of the above protocols. Compounds of the invention which are selective

25

- 5 possess a ratio of at least 10. The compounds of the invention possessing the potency or selectivity desired can be identified by assaying a compound (preferably a small molecule, more preferably a hydroxamic acid, most preferably a compound of formula I) according to the protocols described above and determining the IC_{50} and selectivity ratios.

One group of preferred compounds (more preferably compounds of the formula I) that
 10 can be identified by the methods of the present invention include those inhibitors that possess selective activity against MMP-13 over MMP-1, (preferably an IC_{50} of less than 500nM, more preferably 100nM, most preferably 50nM) for MMP-13 with a selectivity of at least 10 fold, preferably 40 fold, higher for MMP-13 over MMP-1.

PREPARATION OF COMPOUNDS

- 15 The following Examples illustrate the preparation of the compounds of the present invention. Melting points are uncorrected. NMR data are reported in parts per million (δ). Commercial reagents were utilized without further purification. Chromatography refers to column chromatography performed using 32-63 mm silica gel and executed under nitrogen pressure (flash chromatography) conditions. Room or ambient temperature refers to 20-25°C.
 20 All non-aqueous reactions were run under a nitrogen atmosphere for convenience and to maximize yields.

Example 1:

(4R)-1-[4-(4-Fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide

- a) (4R)- 3-[4-(4-Fluorophenoxy)benzyl]-2-oxo-imidazolidine-1,5-dicarboxylic acid
 25 1-benzyl ester 5-tert-butyl ester.

To a solution of (4R)-oxo-imidazolidine-1,5-dicarboxylic acid 1-benzyl ester 5-tert-butyl ester (650 mg, 2.0 mmol) in acetone (10 mL) was added powdered K_2CO_3 (550 mg,) and 4-(4-fluorophenoxy)benzylbromide (1.85 g, 6.6 mmol). The reaction mixture was stirred at room temperature for 6 days and then the Solvent was evaporated. The residue was
 30 taken up in ethyl acetate and washed with water and brine. After drying over $MgSO_4$, the solvent was evaporated. The title compound (820 mg, 78%) was isolated from the residue by chromatography on silica gel eluting with chloroform.

b) (4R)-1-[4-(4-Fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid
 tert-butyl ester

- 35 A solution of (4R)-3-[4-(4-fluorophenoxy)benzyl]-2-oxo-imidazolidine-1,5-dicarboxylic acid 1-benzyl ester 5-tert-butyl ester (1.1 g, 2.1 mmol) in methanol (100 mL) was hydrogenated over 10% Pd on carbon (110 mg) at 3 atmospheres pressure for 6 hours. After removal of the catalyst by filtration through a 0.45 μ m pore nylon filter, the solvent was evaporated to afford the title compound (810 mg, 100%) as a yellow solid.

- 40 c) (4R)-1-[4-(4-Fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid

5 A solution of (4R)-1-[4-(4-fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid tert-butyl ester (810 mg, 1.56 mmol) in CH₂Cl₂ (8 mL) was treated with trifluoroacetic acid (8 mL). The reaction mixture was stirred at room temperature for 2.5 hours and concentrated to leave an oil. The title compound, a white solid (297 mg, 58%), was collected by filtration, after triturating the oil with a mixture of warm diethyl ether and hexane.

10 d) (4R)-1-[4-(4-Fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid(2-trimethylsilanylethoxy)amide.

To a solution of (4R)-1-[4-(4-fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid (120 mg, 0.36 mmol) in methylene chloride (5 mL) were added sequentially 1-hydroxybenztriazole (73 mg, 0.54 mmol), diisopropylethylamine (0.13 mL, 0.75 mmol),
15 O-(2-trimethylsilylethyl)hydroxylamine hydrochloride (92 mg, 0.54 mmol) and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (104 mg, 0.54 mmol). The reaction mixture was stirred at room temperature for 16 hours and was then diluted with methylene chloride and water. The organic phase was washed successively with aqueous 1M HCl solution, water, aqueous saturated NaHCO₃ solution and brine. After drying over MgSO₄,
20 the solution was concentrated to an oil. The title compound, an oil (85 mg, 53%), was isolated by chromatography on silica gel eluting with ethyl acetate.

e) (4R)-1-[4-(4-Fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide

To a solution of (4R)-1-[4-(4-fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic
25 acid (2-trimethylsilanylethoxy)amide (85 mg, 0.19 mmol) in methylene chloride (5 mL) was added boron trifluoride etherate (0.073 mL, 0.58 mmol). The reaction mixture was stirred at room temperature for 1.5 hours and then quenched by addition of aqueous saturated NH₄Cl solution. The mixture was diluted with water and ethyl acetate and the organic phase was washed with brine, dried over MgSO₄ and concentrated to a white solid. The title compound
30 (31 mg, 47%) was isolated by recrystallization from a mixture of ethyl acetate and methanol.

¹H NMR (DMSO-d₆): δ 10.63 (br s, 1 H), 8.93 (br s, 1 H), 7.23 - 7.17 (m, 4 H), 7.05 - 7.01 (m, 2 H), 6.92 (d, J = 8.7 Hz, 2 H), 6.76 (s, 1 H), 4.22 (d, J = 15.2 Hz, 1H), 4.15 (d, J = 15.2 Hz, 1 H), 3.92 - 3.89 (m, 1 H), 3.40 (apparent t, J = 9.1 Hz, 1 H), 3.15 - 3.12 (m, 1 H). MS m/z 344 (M-1). Analysis calculated for C₁₉H₁₆FN₃O₄: C, 59.13; H, 4.67; N, 12.17. Found: C, 58.98; H, 4.83; N, 12.10.

Example 2:

(4R)-1-[4-(Naphthalen-1-yloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide.

MS m/z 376 (M-1). Analysis calculated for C₂₁H₁₉N₃O₄: C, 66.83; H, 5.07; N, 11.13. Found: C, 66.75; H, 5.30; N, 11.13.

5

Example 3:

(4R)-1-[4-(Naphthalen-2-yloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide.

MS m/z 376 (M-1). Analysis calculated for $C_{21}H_{19}N_3O_4 + 0.5 H_2O$: C, 65.28; H, 5.22; N, 10.87. Found: C, 65.01; H, 5.12; N, 11.28.

10

Example 4:

(4R)-1-(4-Methoxybenzyl)-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide

M.p. 130-133 C. MS m/z 264 (M-1). Analysis calculated for $C_{12}H_{15}N_3O_4$: C, 54.33; H, 5.70; N, 15.84. Found: C, 54.24; H, 5.77; N, 15.62.

Example 5:

15

(4R)-1-[3-(4-Fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide.

MS m/z 344 (M-1). Analysis calculated for $C_{19}H_{16}FN_3O_4$: C, 59.13; H, 4.67; N, 12.17. Found: C, 59.24; H, 4.60; N, 12.42.

Example 6:

(4R)-1-Naphthalen-2-ylmethyl-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide.

20

MS m/z 284 (M-1). Analysis calculated for $C_{15}H_{15}N_3O_3$: C, 63.15; H, 5.30; N, 14.73. Found: C, 62.82; H, 5.32; N, 14.49.

Example 7:

(4R)-1-(4'-Fluorobiphenyl-4-ylmethyl)-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide

MS m/z 328 (M-1). Analysis calculated for $C_{17}H_{16}FN_3O_3 + 0.5 H_2O$: C, 60.35; H, 5.06; N, 12.42. Found: C, 60.43; H, 4.99; N, 12.83.

Example 8:

(4R)-1-(4-Benzyloxybenzyl)-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide

MS m/z 340 (M-1). Analysis calculated for $C_{18}H_{19}N_3O_4$: C, 63.33; H, 5.61; N, 12.31. Found: C, 63.13; H, 5.62; N, 12.28.

30

Example 9:

(4R)-1-[4-(2-Chloro-4-fluorobenzyloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide.

MS m/z 392, 394 (M-1). Analysis calculated for $C_{18}H_{17}ClFN_3O_4 + 0.5 H_2O$: C, 53.67; H, 4.50; N, 10.43. Found: C, 53.78; H, 4.51; N, 10.15.

35


50190-65

-33-

CLAIMS:

5

1. A compound according to formula (1)



or a pharmaceutically acceptable salt or solvate thereof, wherein


- R¹ is (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₁-C₉)heteroaryl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₉)heteroaryl, (C₁-C₉)heteroaryl(C₁-C₉)heteroaryl, (C₆-C₁₀)aryloxy(C₆-C₁₀)aryl, (C₁-C₉)heteroaryloxy(C₆-C₁₀)aryl, (C₆-C₁₀)aryloxy(C₁-C₉)heteroaryl, (C₁-C₉)heteroaryloxy(C₁-C₉)heteroaryl, (C₆-C₁₀)aryloxy(C₁-C₆)alkyl, (C₁-C₉)heteroaryloxy(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl(C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(C₁-C₆)alkyl(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₆)alkyl(C₁-C₉)heteroaryl, (C₁-C₉)heteroaryl(C₁-C₆)alkyl(C₁-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(C₁-C₆)alkoxy(C₆-C₁₀)aryl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₁-C₉)heteroaryl, (C₁-C₉)heteroaryl(C₁-C₆)alkoxy(C₁-C₉)heteroaryl, (C₆-C₁₀)aryloxy(C₁-C₆)alkyl(C₆-C₁₀)aryl, (C₁-C₉)heteroaryloxy(C₁-C₆)alkyl(C₆-C₁₀)aryl, (C₆-C₁₀)aryloxy(C₁-C₆)alkyl(C₁-C₉)heteroaryl, (C₁-C₉)heteroaryloxy(C₁-C₆)alkyl(C₁-C₉)heteroaryl, (C₆-C₁₀)aryl(C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₁-C₉)heteroaryl(C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₉)heteroaryl(C₁-C₆)alkyl, (C₁-C₉)heteroaryl(C₁-C₉)heteroaryl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy(C₁-C₆)alkyl, or (C₁-C₉)heteroaryl(C₁-C₆)alkoxy(C₁-C₆)alkyl,

- wherein, independently, each of the ring carbon atoms of the (C₆-C₁₀)aryl and (C₁-C₉)heteroaryl moieties that is capable of forming an additional bond is optionally substituted by a group selected from fluoro, chloro, bromo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, and perfluoro(C₁-C₃)alkyl, and perfluoro(C₁-C₃)alkoxy;

R² and R³ are each independently selected from hydrogen and (C₁-C₆)alkyl, or taken together form a spiro ring of the formula

50190-65


34



wherein * is the spiro ring point of attachment to the carbon to which R^2 and R^3 are attached, X is a bond, CH_2 , O, S, NH or $N(C_1-C_6)$ alkyl, n is independently 1 or 2, and m is independently 1 or 2; and

5 R^4 is hydrogen or (C_1-C_6) alkyl.

2. The compound, salt or solvate according to claim 1 of the formula (I')



3. The compound, salt or solvate according to claim 1 or 2, wherein R^2 , R^3 and R^4 are hydrogen.

10 4. The compound, salt or solvate according to claim 1 or 2, wherein R^4 is hydrogen.

5. The compound, salt or solvate according to claim 1 or 2, wherein R^4 is (C_1-C_6) alkyl.


15 6. The compound, salt or solvate according to claim 1, 2 or 5, wherein R^2 and R^3 are hydrogen.

7. The compound, salt or solvate according to claim 1, 2 or 5, wherein R^2 and R^3 are (C_1-C_6) alkyl such that R^2 is the same as R^3 .

50190-65

34a

8. The compound, salt or solvate according to claim 1, 2, 4 or 5, wherein R^2 and R^3 taken together form a spiro ring of the formula



5 wherein * is the spiro ring point of attachment to the carbon to which R^2 and R^3 are attached, X is a bond, CH_2 , O, S, NH or $N(C_1-C_6)$ alkyl, n is 1 or 2, and m is 1 or 2 such that n is the same as m.

9. The compound, salt or solvate according to any one of claims 1 to 8, wherein R^1 is 4-(4-fluorophenoxy)phenyl.

10 10. The compound, salt or solvate according to any one of claims 1 to 8, wherein R^1 is 4-(4-chlorophenoxy)phenyl.

11. The compound, salt or solvate according to any one of claims 1 to 8, wherein R^1 is 4-(naphthalen-2-yloxy)phenyl.

12. The compound, salt or solvate according to claim 1,
15 wherein the compound is selected from the group consisting of:

(4R)-1-[4-(4-Fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide;

20 (4R)-1-[4-(Naphthalen-1-yloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide;

(4R)-1-[4-(Naphthalen-2-yloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide;

(4R)-1-(4-Methoxybenzyl)-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide;

50190-65

34b

(4R)-1-[3-(4-Fluorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide;

(4R)-1-Naphthalen-2-ylmethyl-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide;

50190-65

-35-

5 (4*R*)-1-(4'-Fluorobiphenyl-4-ylmethyl)-2-oxo-imidazolidine-4-carboxylic acid
hydroxyamide;

(4*R*)-1-(4-Benzoyloxybenzyl)-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide; and

(4*R*)-1-[4-(2-Chloro-4-fluorobenzyloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid
hydroxyamide.

10 13. The compound, salt or solvate according to
claim 1, wherein the compound is selected from the group
consisting of:

(4*R*)-1-[4-(4-Chlorophenoxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid
hydroxyamide;

(4*R*)-1-[4-(4-Fluorophenoxy)benzyl]-2-oxo-7-oxa-1,3-diazaspiro[4.4]nonane-4-
carboxylic acid hydroxyamide;

15 (4*R*)-2-Oxo-1-[4-(pyridin-4-yloxy)benzyl]imidazolidine-4-carboxylic acid
hydroxyamide;

(4*R*)-4-Methyl-2-oxo-1-[4-(pyridin-4-yloxy)benzyl]imidazolidine-4-carboxylic acid
hydroxyamide;

(4*R*)-5,5-Dimethyl-2-oxo-1-[4-(pyridin-4-yloxy)benzyl]imidazolidine-4-carboxylic acid
20 hydroxyamide;

(4*R*)-1-[4-(4-Fluorophenoxy)benzyl]-5,5-dimethyl-2-oxo-imidazolidine-4-carboxylic
acid hydroxyamide;

(4*R*)-1-[4-(4-Chlorophenoxy)benzyl]-5,5-dimethyl-2-oxo-imidazolidine-4-carboxylic
acid hydroxyamide;

25 (4*R*)-1-[4-(4-Fluorophenoxy)benzyl]-4-methyl-2-oxo-imidazolidine-4-carboxylic acid
hydroxyamide;

(4*R*)-1-[4-(4-Chlorophenoxy)benzyl]-4-methyl-2-oxo-imidazolidine-4-carboxylic acid
hydroxyamide;

(4*R*)-1-[4-(4-Fluorophenoxy)benzyl]-2-oxo-1,3-diazaspiro[4.4]nonane-4-carboxylic
30 acid hydroxyamide;

(4*R*)-1-[4-(4-Chlorophenoxy)benzyl]-2-oxo-1,3-diazaspiro[4.4]nonane-4-carboxylic
acid hydroxyamide;

(4*R*)-1-[4-(4-Fluorophenoxy)benzyl]-4,5,5-trimethyl-2-oxo-imidazolidine-4-carboxylic
acid hydroxyamide;

35 (4*R*)-1-[4-(4-Chlorophenoxy)benzyl]-4,5,5-trimethyl-2-oxo-imidazolidine-4-carboxylic
acid hydroxyamide;

(4*R*)-4-Methyl-1-[4-(naphthalen-2-yloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic acid
hydroxyamide;

(4*R*)-5,5-Dimethyl-1-[4-(naphthalen-2-yloxy)benzyl]-2-oxo-imidazolidine-4-carboxylic
40 acid hydroxyamide;

64680-1237

36

(4R)-1-[4-(5-Fluoropyridin-2-yloxy)benzyl]-4-methyl-2-oxo-imidazolidine-4-carboxylic acid hydroxyamide;

(4R)-2-Oxo-1-(4-pyridin-4-ylbenzyl)imidazolidine-4-carboxylic acid hydroxyamide; and

5 (4R)-2-Oxo-1-(4-pyridylmethyl)imidazolidine-4-carboxylic acid hydroxyamide.

14. The compound, salt or solvate according to any one of claims 2 to 8, wherein $-\text{CH}_2-\text{R}^1$ is 4-(4-fluorophenoxy)benzyl, 4-(naphthalen-1-yloxy)benzyl, 4-(naphthalen-2-yloxy)benzyl, 10 4-methoxybenzyl, 3-(4-fluorophenoxy)benzyl, naphthalen-2-ylmethyl, 4'-fluorobiphenyl-4-ylmethyl, 4-benzyloxybenzyl, 4-(2-chloro-4-fluorobenzyloxy)benzyl, 4-(4-chlorophenoxy)benzyl, 4-(pyridin-4-yloxy)benzyl, 4-(5-fluoropyridin-2-yloxy)benzyl, 4-pyridin-4-ylbenzyl or 4-pyridylmethyl.

15. A pharmaceutical composition for the treatment of a condition selected from the group consisting of arthritis, inflammatory bowel disease, Crohn's disease, emphysema, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions, 20 inflammation, allergic contact hypersensitivity, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis, aortic aneurysm, congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, 25 spinal cord injury, neuro-degenerative disorders, autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, 30 corneal injury, macular degeneration, abnormal wound healing, burns, diabetes, tumor invasion, tumor growth, tumor

50190-65

37

metastasis, corneal scarring, scleritis, AIDS, sepsis and septic shock in a mammal, which comprises:

(a) an amount of the compound, salt or solvate of any one of claims 1 to 14, effective in such treatment, and

5 (b) a pharmaceutically acceptable carrier.

16. A pharmaceutical composition for the treatment of a condition which can be treated by the inhibition of matrix metalloproteinases in a mammal, which comprises:

10 (a) an amount of the compound, salt or solvate of any one of claims 1 to 14, effective in such treatment, and

(b) a pharmaceutically acceptable carrier.


17. A pharmaceutical composition for the treatment of a condition which can be treated by the inhibition of a mammalian reprotolysin in a mammal, which comprises:

15 (a) an amount of the compound, salt or solvate of any one of claims 1 to 14, effective in such treatment, and

(b) a pharmaceutically acceptable carrier.

18. The pharmaceutical composition according to claim 15, 16 or 17, which is in a dosage unit form containing
20 the compound, salt or solvate at a dose of 0.1 to 25 mg/kg body weight of a subject to be treated per day.

19. A commercial package comprising the pharmaceutical composition of claim 15, 16, 17 or 18, and instructions for the use thereof for treating the condition.



(I)